Effects of exercise on heart health in breast cancer patients
Cardioprotective Effect of Acute Exercise in Breast Cancer Patients
This study tests if doing different types of exercise right before chemotherapy can help protect the hearts of women with early-stage breast cancer from damage caused by the treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Technical University of Madrid Academic / other |
| Drugs / interventions | chemotherapy, doxorubicin |
| Locations | 1 site (Madrid) |
| Trial ID | NCT05467111 on ClinicalTrials.gov |
What this trial studies
This study investigates whether acute exercise performed 24 hours before chemotherapy can reduce cardiac damage in women with early-stage breast cancer receiving doxorubicin. The research focuses on measuring levels of NT-proBNP, a biomarker for heart muscle damage, to assess the cardioprotective effects of different types of exercise, including aerobic, strength, or a combination of both. By analyzing the impact of exercise on cardiotoxicity across multiple chemotherapy cycles, the study aims to provide a feasible and low-cost intervention for improving patient outcomes.
Who should consider this trial
Good fit: Ideal candidates are women with non-metastatic breast cancer who are scheduled to receive neoadjuvant doxorubicin chemotherapy.
Not a fit: Patients who have pre-existing cardiovascular disease or other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce heart-related side effects in breast cancer patients undergoing chemotherapy.
How similar studies have performed: While the specific approach of this study is novel, previous research has indicated that exercise can have beneficial effects on cardiac health in cancer patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Woman with non-metastatic breast cancer not previously treated. * Scheduled to receive neoadjuvant doxorubicin chemotherapy. * Receive the oncologist´s approval for the practice of exercise. * Acceptance of randomization. * To sign an informed consent form before starting any measurement or procedure related to the project. Exclusion Criteria: * Patients who receive initial surgery and who are not going to receive neoadjuvant treatment. * Contraindications to perform stress tests following the recommendations of the American Thoracic Society. * Pre-existing cardiovascular disease. * Body mass index (BMI) \> 35 kg/m2. * Diabetes mellitus. * Renal disease. * Severe anemia. * Pregnacy. * Current smoking status.
Where this trial is running
Madrid
- "Ramón y Cajal" Hospital — Madrid, Spain (Recruiting)
Study contacts
- Study coordinator: María Alonso
- Email: maria.alonsod@alumnos.upm.es
- Phone: + 34 678942096
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.